SLONIN JONATHAN 4

What Happened
Jonathan Slonin, Chief Medical Officer of Pacira BioSciences (PCRX), received a grant of 54,546 restricted stock units (RSUs) on February 11, 2026. The reported acquisition price is $0.00 and the filing lists the transaction as an award (code A). These RSUs represent contingent rights to receive common shares in the future rather than immediately issued shares.

Key Details

• Transaction date and type: 2026-02-11 — Award/grant of 54,546 RSUs (code A) at $0.00.
• Report filed: Form 4 filed 2026-02-13 (appears timely; Form 4 is generally due within two business days).
• Shares owned after transaction: Not specified in the provided filing summary.
• Footnote: F1 — RSUs vest in four equal annual installments beginning February 15, 2027, contingent on continuous service; each RSU equals the right to one share.

Context
RSUs are compensation awards that convert into actual shares only upon vesting; they do not represent immediate market purchases or sales. Because vesting here is spread over four years and is service-contingent, this grant reflects typical long-term incentive compensation rather than an immediate change in Slonin’s publicly tradable holdings.